Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

It's not hard to see why investors may be bullish on Recursion's business when you hear its CEO hype up its potential. Last year, CEO Chris Gibson wasn't holding back on the savings he believed the ...

Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, however, is to examine the stocks held by highly successful companies. For example, Nvidia owns stakes in ...

Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...